Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-13 01:00 | 2026-01-12 | AKTS | Akoustis Technologies Inc. | Kim Helen Susan | Director, 10% owner | BUY | $18.00 | 835,000 | $15,030,000 | 157,387 |
| 2026-01-13 00:21 | 2026-01-09 | QURE | uniQure N.V. | Kaye Jack | Director | OPT+S | $27.28 | 6,390 | $174,319 | 20,439 |
| 2026-01-13 01:09 | 2026-01-08 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.59 | 91,374 | $53,536 | 2,309,869 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $76.45 | 2,514 | $192,195 | 394,453 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Utter Christine Marie | Officer | SELL | $76.45 | 1,034 | $79,049 | 72,693 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Golden Lee Scott | Officer | SELL | $76.45 | 866 | $66,206 | 92,428 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | SELL | $77.06 | 6,347 | $489,081 | 111,312 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | SELL | $76.45 | 940 | $71,863 | 6,791 |
| 2026-01-13 01:20 | 2026-01-08 | PTCT | PTC THERAPEUTICS, INC. | Pauwels Eric | Officer | SELL | $77.02 | 7,348 | $565,946 | 80,141 |
| 2026-01-13 00:10 | 2026-01-08 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $1.82 | 1,281 | $2,336 | 1,035,925 |
| 2026-01-10 01:08 | 2026-01-07 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $85.08 | 44,199 | $3,760,579 | 17,494 |
| 2026-01-10 01:34 | 2026-01-08 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | Officer | SELL | $8.00 | 15,000 | $120,000 | 1,685,426 |
| 2026-01-10 00:05 | 2026-01-07 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $474.99 | 4,500 | $2,137,455 | 42,293 |
| 2026-01-10 01:37 | 2026-01-08 | EQ | Equillium, Inc. | Tom Penny | Officer | SELL | $1.29 | 6,533 | $8,428 | 0 |
| 2026-01-10 00:35 | 2026-01-08 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | SELL | $41.89 | 12,000 | $502,680 | 19,086 |
| 2026-01-10 01:15 | 2026-01-07 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $331.76 | 664 | $220,289 | 0 |
| 2026-01-10 01:13 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Director, Officer | SELL | $72.23 | 8,576 | $619,444 | 283,394 |
| 2026-01-10 01:13 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | Calderaro Charles III | Officer | SELL | $72.23 | 3,727 | $269,201 | 49,797 |
| 2026-01-10 01:13 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | Officer | SELL | $72.23 | 1,965 | $141,932 | 116,867 |
| 2026-01-10 01:12 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | SELL | $72.23 | 2,373 | $171,402 | 36,494 |
| 2026-01-10 01:12 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Officer | SELL | $72.23 | 2,373 | $171,402 | 91,627 |
| 2026-01-10 04:30 | 2026-01-08 | MNKD | MANNKIND CORP | Tross Stuart A | Officer | SELL | $6.33 | 47,006 | $297,548 | 985,007 |
| 2026-01-10 03:34 | 2026-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | Director, Officer | SELL | $0.00 | 11,582 | $0 | 378,859 |
| 2026-01-10 01:12 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | Moriarty John B | Officer | SELL | $72.23 | 2,374 | $171,474 | 74,557 |
| 2026-01-10 02:59 | 2026-01-08 | ARDX | Ardelyx Inc. | Williams Laura A | Officer | OPT+S | $6.98 | 50,000 | $348,900 | 361,563 |
| 2026-01-10 00:53 | 2026-01-07 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Director, Officer | SELL | $2.25 | 43,500 | $97,875 | 303,721 |
| 2026-01-10 01:12 | 2026-01-07 | RNA | Avidity Biosciences, Inc. | MacLean Michael F | Officer | SELL | $72.23 | 1,974 | $142,582 | 63,832 |
| 2026-01-10 03:16 | 2026-01-08 | ANAB | AnaptysBio Inc. | Lizzul Paul F. | Officer | OPT+S | $44.71 | 3,650 | $163,192 | 42,088 |
| 2026-01-10 03:12 | 2026-01-08 | ANAB | AnaptysBio Inc. | Faga Daniel | Director, Officer | OPT+S | $44.71 | 14,281 | $638,504 | 479,344 |
| 2026-01-10 00:10 | 2026-01-08 | ALT | Altimmune, Inc. | Pisano Wayne | Director | BUY | $4.08 | 5,000 | $20,410 | 13,498 |
| 2026-01-09 20:27 | 2026-01-08 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.69 | 13,000 | $34,953 | 0 |
| 2026-01-10 03:14 | 2026-01-08 | ANAB | AnaptysBio Inc. | MULROY DENNIS | Officer | OPT+S | $44.71 | 2,515 | $112,446 | 21,852 |
| 2026-01-10 03:13 | 2026-01-08 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $44.71 | 2,210 | $98,809 | 12,835 |
| 2026-01-10 05:42 | 2026-01-07 | ZBIO | Zenas BioPharma, Inc. | MOULDER LEON O JR | Director, Officer | BUY | $16.39 | 100,000 | $1,639,000 | 366,155 |
| 2026-01-09 00:00 | 2026-01-07 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,103.48 | 292,148 | $322,380,731 | 91,896,978 |
| 2026-01-09 04:42 | 2026-01-07 | XCUR | EXICURE, INC. | Exicure HiTron Inc. | 10% owner | SELL | $4.50 | 741,272 | $3,335,724 | 2,592,061 |
| 2026-01-09 00:03 | 2026-01-07 | REGN | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L | Director | OPT+S | $800.00 | 1,500 | $1,200,000 | 1,703 |
| 2026-01-09 00:05 | 2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Cohen Joshua B | Director, Officer | SELL | $11.09 | 7,715 | $85,596 | 3,317,632 |
| 2026-01-09 00:05 | 2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Klee Justin B. | Director, Officer | SELL | $11.09 | 7,715 | $85,589 | 3,317,586 |
| 2026-01-09 01:23 | 2026-01-08 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $30.00 | 5,000 | $150,005 | 61,740 |
| 2026-01-09 00:20 | 2026-01-06 | RNAC | Cartesian Therapeutics, Inc. | Brunn Carsten | Director, Officer | SELL | $6.82 | 23,766 | $162,077 | 323,530 |
| 2026-01-09 00:19 | 2026-01-06 | RNAC | Cartesian Therapeutics, Inc. | Miljkovic Milos | Officer | SELL | $6.82 | 3,573 | $24,367 | 58,820 |
| 2026-01-09 00:19 | 2026-01-06 | RNAC | Cartesian Therapeutics, Inc. | Davis Blaine | Officer | SELL | $6.82 | 10,591 | $72,227 | 121,220 |
| 2026-01-09 04:15 | 2026-01-06 | PBYI | PUMA BIOTECHNOLOGY, INC. | HUNT DOUGLAS M | Officer | SELL | $5.86 | 8,987 | $52,695 | 155,907 |
| 2026-01-09 04:14 | 2026-01-06 | PBYI | PUMA BIOTECHNOLOGY, INC. | NOUGUES MAXIMO F | Officer | SELL | $5.86 | 10,945 | $64,187 | 193,284 |
| 2026-01-09 00:11 | 2026-01-07 | ANAB | AnaptysBio Inc. | Lizzul Paul F. | Officer | OPT+S | $45.11 | 2,235 | $100,821 | 37,213 |
| 2026-01-09 00:10 | 2026-01-07 | ANAB | AnaptysBio Inc. | Faga Daniel | Director, Officer | OPT+S | $45.11 | 9,202 | $415,102 | 466,787 |
| 2026-01-09 05:20 | 2026-01-07 | ERAS | Erasca, Inc. | Garner Ebun | Officer | OPT+S | $5.59 | 120,000 | $670,812 | 25,076 |
| 2026-01-09 00:05 | 2026-01-06 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $53.35 | 20,000 | $1,066,914 | 70,000 |
| 2026-01-09 04:27 | 2026-01-06 | PBYI | PUMA BIOTECHNOLOGY, INC. | AUERBACH ALAN H | Director, Officer, 10% owner | SELL | $5.86 | 34,950 | $204,877 | 7,145,951 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.